Suprax Tablets Dosage
Generic name: CEFIXIME 100mgCEFIXIME 200mg
Dosage form: tablet, chewable
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
ALL RECOMMENDED DOSAGE FOR CEFIXIME SUSPENSION ARE INCLUDED IN THIS SECTION FOR INFORMATIONAL PURPOSE ONLY. SUPRAX (CEFIXIME) CHEWABLE TABLETS 100 MG ARE APPROPRIATE FOR A 100 MG DOSE, SUPRAX (CEFIXIME) CHEWABLE TABLETS 150 MG ARE APPROPRIATE FOR A 150 MG DOSE AND SUPRAX (CEFIXIME) CHEWABLE TABLETS 200 MG ARE APPROPRIATE FOR A 200 MG DOSE.
SUPRAX (CEFIXIME) CHEWABLE TABLETS MUST BE CHEWED OR CRUSHED BEFORE SWALLOWING.
Adults: The recommended dose is 400 mg daily. For the treatment of uncomplicated cervical/urethral gonococcal infections, a single oral dose of 400 mg is recommended.
Children: The recommended dose is 8 mg/kg/day of the cefixime. This may be administered as a single daily dose or may be given in two divided doses, as 4 mg/kg every 12 hours.
|PEDIATRIC DOSAGE CHART
|100 mg/5 mL
||200 mg/5 mL
||Suprax (cefixime) Chewable Tablet
tsp of Suspension
tsp of Suspension
||1 tablet of 100 mg
||1 tablet of 150 mg
||1 tablet of 200 mg
||1 tablet of 100 mg and 1 tablet of 150 mg
||2 tablets of 150 mg
Otitis media should be treated with Suprax (cefixime) chewable tablets or suspension. Clinical studies of otitis media were conducted with Suprax (cefixime) chewable tablets or suspension, and the Suprax (cefixime) chewable tablets or suspension results in higher peak blood levels than the immediate-release tablets when administered at the same dose. Therefore, the immediate-release tablets should not be substituted for Suprax (cefixime) chewable tablets or suspension in the treatment of otitis media. (See CLINICAL PHARMACOLOGY.)
Efficacy and safety in infants aged less than six months have not been established.
In the treatment of infections due to S. pyogenes, a therapeutic dosage of Suprax (cefixime) chewable tablets should be administered for at least 10 days.
Suprax (cefixime) chewable tablets may be administered in the presence of impaired renal function. Normal dose and schedule may be employed in patients with creatinine clearances of 60 mL/min or greater. Patients whose clearance is between 21 and 60 mL/min or patients who are on renal hemodialysis may be given 75% of the standard dosage at the standard dosing interval (i.e., 300 mg daily). Patients whose clearance is < 20 mL/min, or patients who are on continuous ambulatory peritoneal dialysis may be given half the standard dosage at the standard dosing interval (i.e., 200 mg daily). Neither hemodialysis nor peritoneal dialysis remove significant amounts of drug from the body.